Genzyme Myozyme BLA For Pompe Disease Could Clear FDA By January
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme expects its BLA for Myozyme (alglucosidase alfa) will receive a priority review from FDA for treatment of Pompe disease, the firm said July 29